FOLR2 and neoplasm: SMDCs are not the only group of treatments available for FR positive tumours, and the development of anti-folate antibodies that preferentially target FRα or FRβ with specificity and selectivity (as they do not possess an indiscriminate folic acid targeting moiety) represents an alternative strategy.10